RVNC (Revance Therapeutics Inc.): Time to Pay Attention?

The price of Revance Therapeutics Inc. (NASDAQ: RVNC) closed at $31.70 in the last session, up 8.60% from day before closing price of $29.19. In other words, the price has increased by $+2.51 from its previous closing price. On the day, 2799141 shares were traded. RVNC stock price reached its highest trading level at $31.92 during the session, while it also had its lowest trading level at $29.20.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.



We take a closer look at RVNC’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 5.30 and its Current Ratio is at 5.60. In the meantime, Its Debt-to-Equity ratio is 2.67 whereas as Long-Term Debt/Eq ratio is at 2.60.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on October 11, 2022, initiated with a Equal-Weight rating and assigned the stock a target price of $27.

On September 22, 2022, Goldman started tracking the stock assigning a Buy rating and target price of $33.

Wells Fargo Downgraded its Overweight to Equal Weight on October 25, 2021, whereas the target price for the stock was revised from $35 to $17.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 09 when Schilke Tobin sold 3,701 shares for $27.16 per share. The transaction valued at 100,525 led to the insider holds 58,877 shares of the business.

Moxie Dwight sold 11,000 shares of RVNC for $297,798 on Sep 14. The SVP, GC & Secretary now owns 31,694 shares after completing the transaction at $27.07 per share.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 22.11 while its Price-to-Book (P/B) ratio in mrq is 15.69.

Stock Price History:

Over the past 52 weeks, RVNC has reached a high of $30.95, while it has fallen to a 52-week low of $11.27. The 50-Day Moving Average of the stock is 22.48, while the 200-Day Moving Average is calculated to be 19.94.

Shares Statistics:

According to the various share statistics, RVNC traded on average about 1.47M shares per day over the past 3-months and 3.08M shares per day over the past 10 days. A total of 82.27M shares are outstanding, with a floating share count of 79.47M. Insiders hold about 1.10% of the company’s shares, while institutions hold 89.40% stake in the company. Shares short for RVNC as of Oct 13, 2022 were 9.52M with a Short Ratio of 13.06M, compared to 8.04M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 11.57% and a Short% of Float of 11.84%.

Earnings Estimates

The company has 6 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.89 for the current quarter, with a high estimate of -$0.69 and a low estimate of -$1, while EPS last year was -$1.1. The consensus estimate for the next quarter is -$0.83, with high estimates of -$0.61 and low estimates of -$0.99.

Analysts are recommending an EPS of between -$2.62 and -$3.75 for the fiscal current year, implying an average EPS of -$3.37. EPS for the following year is -$2.78, with 6 analysts recommending between -$1.8 and -$3.98.

Revenue Estimates

According to 11 analysts, the current quarter’s revenue is expected to be $27.94M. It ranges from a high estimate of $31.8M to a low estimate of $23.6M. As of the current estimate, Revance Therapeutics Inc.’s year-ago sales were $19.75M, an estimated increase of 41.50% from the year-ago figure. For the next quarter, 11 analysts are estimating revenue of $38.45M, an increase of 48.20% over than the figure of $41.50% in the same quarter last year. There is a high estimate of $46M for the next quarter, whereas the lowest estimate is $29.2M.

A total of 12 analysts have provided revenue estimates for RVNC’s current fiscal year. The highest revenue estimate was $130M, while the lowest revenue estimate was $107.6M, resulting in an average revenue estimate of $120.08M. In the same quarter a year ago, actual revenue was $77.8M, up 54.30% from the average estimate. Based on 12 analysts’ estimates, the company’s revenue will be $219.28M in the next fiscal year. The high estimate is $270M and the low estimate is $163.9M. The average revenue growth estimate for next year is up 82.60% from the average revenue estimate for this year.